Results 201 to 210 of about 158,362 (293)

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

open access: yesAdvanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang   +6 more
wiley   +1 more source

Corrigendum: Dysfunctional epileptic neuronal circuits and dysmorphic dendritic spines are mitigated by platelet-activating factor receptor antagonism. [PDF]

open access: yesSci Rep, 2016
Musto AE   +8 more
europepmc   +1 more source

Receptor antagaonists of platelet-activating factor

open access: yesJapanese Journal of Pharmacology, 1997
openaire   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

open access: yesAdvanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård   +19 more
wiley   +1 more source

Dysfunctional epileptic neuronal circuits and dysmorphic dendritic spines are mitigated by platelet-activating factor receptor antagonism. [PDF]

open access: yesSci Rep, 2016
Musto AE   +8 more
europepmc   +1 more source

A Nanobody‐LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
Plastin‐2 (PLS2) is identified as a dual‐function receptor on DCs that mediates both nanoparticle uptake and immunomodulation. A nanobody‐LNP platform is engineered to integrate antigen delivery with relicensing DCs. The therapeutic strategy elicits potent anti‐tumor T cell responses and leads to significant inhibition of established tumors in vivo ...
Shugang Qin   +9 more
wiley   +1 more source

Early Detection and Inhibition of Post‐Surgical Cancer Recurrence by Synthetic Extracellular Vesicles

open access: yesAdvanced Science, EarlyView.
An implantable hydrogel is designed to hold gene transfection agents engineered to turn early recurrent tumor cells into generators of synthetic EVs. These synthetic EVs can express engineered miR‐26a (E‐miR‐26a) for highly sensitive detection and PD‐1 (a PD‐L1‐blocking agent) for therapeutic intervention, thereby enabling early detection and ...
Junli Zhang   +7 more
wiley   +1 more source

Lithiation‐Driven LiCrSe2 Shell Growth on Metallic CrSe2 Core Governs the Plateau–Slope Behavior

open access: yesAdvanced Science, EarlyView.
Layered CrSe2 is investigated as a lithium‐ion battery cathode combining fast Li+ diffusion and structural reversibility. Calculations and experiments reveal a single topotactic intercalation process with a characteristic plateau–slope profile governed by lithiation‐induced conductivity changes. A core‐shell lithiation evolution underpins its high‐rate
Weihao Li   +15 more
wiley   +1 more source

Microglia‐Targeted Biomimetic Tetrahedral Framework Nucleic Acid Nanovesicles for Synergistic Treatment of Sepsis‐Associated Encephalopathy

open access: yesAdvanced Science, EarlyView.
Sepsis‐associated encephalopathy (SAE) lacks effective therapies. We developed ME@FDsi, a biomimetic nanodrug using a tetrahedral framework nucleic acid to deliver disulfiram and siTNFα. It crosses the blood‐brain barrier, targets M1 microglia, inhibits pyroptosis and inflammation, and scavenges ROS.
Huimin Shi   +15 more
wiley   +1 more source

Tetrahedral DNA Nanostructure‐Based Biomimetic Nanovesicles Attenuate Sepsis‐Associated ARDS by Suppressing Glycolysis via the BMAL1/PFKFB3 Axis

open access: yesAdvanced Science, EarlyView.
Upon inhalation, RM@TNT could persist long‐term in the diseased lungs, while undergoing disintegration to release TNT specifically within the ROS‐rich pathological microenvironments of SA‐ARDS. The released TNT was then precisely delivered to AMs via Tuftsin, where it released Nob intracellularly to activate BMAL1 expression, thus inhibiting AM ...
Yunlong Zhang   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy